Therefore, more studies must be conducted, mainly on HER2+, luminal A and luminal B breast tumors, in order to better understand the mechanism of action of these compounds, which would help to clarify the therapeutic potential in breast cancer subtypes, and even in other cancer types. This evidence concerns the gene ERBB2 and breast carcinoma.